InvestorsHub Logo
Followers 41
Posts 33724
Boards Moderated 0
Alias Born 07/08/2003

Re: tsoprano-1 post# 4693

Wednesday, 08/02/2017 8:14:38 AM

Wednesday, August 02, 2017 8:14:38 AM

Post# of 7747

My guess on the 11mil $1.10 shares is that we wanted money upfront and the doc wanted some equity ownership.



More likely there was a request for a straight cash payment and the request was denied by the Dr.. The "share purchase" was to throw a bone at CYTR. Basically CYTR got a pittance up-front. This deal for a drug that people on this board believe is valued in the billions...really? If you look at deals made for other promising drugs, that aren't as far along the regulatory path as Aldox there is often a large cash payment upfront.

this might help show what a lousy deal this is for CYTR...
https://www.ft.com/content/e552d59c-f2a4-11e4-b914-00144feab7de

http://www.nature.com/nbt/journal/v33/n7/fig_tab/nbt.3278_T7.html?foxtrotcallback=true

“A bank would never get away with what the Department of Education is doing.”

Sheila Bair